The vaccine developer company CanSino said that China’s Central Military Commission has approved the use of the vaccine by the military

Beijing: China’s military has been allowed to use a COVID-19 vaccine candidate Ad5-nCoV after clinical trials proved that using the vaccine was safe and showed some positive results.  The vaccine has been developed by military research unit and CanSino Biologics (6185.HK).

The vaccine developer company CanSino said that China’s Central Military Commission has approved the use of the vaccine by the military on June 25 for a period of one year.

Covid-19 vaccine candidate Ad5-nCoV has been developed by jointly by CanSino and a research institute at the Academy of Military Science. The vaccine is one of China’s eight vaccine candidates approved for human trials at home and abroad for the respiratory disease caused by the coronavirus. The shot also won approval for human testing in Canada.

‘The Ad5-nCoV is currently limited to military use only and its use cannot be expanded to a broader vaccination range without the approval of the Logistics Support Department,’ said CanSino. However, the company doesn’t disclose whether the inoculation of the vaccine candidate is mandatory or optional.

The military approval follows China’s decision earlier this month to offer two other vaccine candidates to employees at state-owned firms travelling overseas.

The company said further that the Phase 1 and 2 clinical trials of the CanSino’s vaccine candidate showed it has the potential to prevent diseases caused by the coronavirus, which has killed half a million people globally, but its commercial success cannot be guaranteed.

The Academy of Military Science separately received approval earlier this month to test its second experimental coronavirus vaccine in humans.

However, no vaccine has yet been approved for commercial use against the fatalities and infection caused by the coronavirus, but over a dozen vaccines from more than 100 candidates globally are being tested in humans.

The Story has originally been published in Reuters

Comments